FDA Clears Cosentyx for Polymyalgia Rheumatica, 11th US Indication
FDA approves Novartis' Cosentyx as first anti-IL-17 biologic for polymyalgia rheumatica; Phase 3 REPLENISH showed 40.5% sustained remission at one year versus 20.5% on placebo.
TAG K-8685 · 431 words on the filing

Summary of findings
- FDA approved Cosentyx (secukinumab) for PMR, its 11th US indication and first anti-IL-17 biologic in the condition
- REPLENISH Phase 3: 40.5% sustained remission at one year on 150 mg vs 20.5% on placebo
- Cosentyx generated $6.7bn in 2025; $5.2bn in first nine months of 2026, up 8% year-on-year
- US patent expiry expected 2029, Europe 2030
- Trial recorded a fatal case of cryptococcal meningitis in the Cosentyx group
The FDA has approved Novartis' Cosentyx (secukinumab) for adults with polymyalgia rheumatica who cannot tolerate corticosteroids or respond inadequately to them. The decision makes Cosentyx the first anti-IL-17 biologic authorised for PMR and its 11th approved indication in the United States.
The clearance covers a population with genuinely thin options. PMR is an inflammatory disorder that primarily hits adults over 50, producing pain and stiffness in the shoulders, neck and hips. Novartis puts the US prevalence at nearly 1 million people. Corticosteroids remain the standard of care, yet roughly 40% of patients relapse within the first year, and prolonged steroid exposure carries serious adverse effects of its own.
What did the REPLENISH trial show?
The approval rests on the Phase 3 REPLENISH trial, which tested 300 mg and 150 mg doses of Cosentyx against placebo, with all arms running a 24-week corticosteroid taper. At one year, the 150 mg group achieved sustained remission in 40.5% of patients against 20.5% on placebo — a doubling, though still leaving the majority of treated patients short of remission. Novartis' announcement did not break out the 300 mg arm's results.
John Stone, M.D., of Harvard Medical School and global principal investigator of the trial, said: "For too long, treatment options beyond glucocosteroids have been limited." The safety profile warrants attention: reported adverse events included eczema, dermatitis, rashes, urticaria and urinary tract infections. The study also recorded a serious UTI and a fatal case of cryptococcal meningitis in the Cosentyx group.
Why the timing matters for Novartis
The approval lands as Cosentyx faces intensifying competition and a US patent expiration expected in 2029, with Europe following in 2030. The franchise generated $6.7 billion in revenue in 2025, and the first nine months of 2026 brought $5.2 billion — an 8% year-on-year increase. Each new indication extends the label's reach, but none of them delays the cliff.
Victor Bultó, president of Novartis' US business, said: "With this approval in PMR, our 11th U.S. indication for Cosentyx, we are expanding those benefits to a community that has had limited treatment options for far too long."
Bultó added: "This milestone reflects our commitment to continually investigate where our medicines can help patients most, extending the impact of proven innovations to new areas of significant unmet need."
For portfolio planners, the calculus is straightforward. A first-in-class label in PMR adds a niche but underserved population to an aging blockbuster. Whether that offsets biosimilar pressure after 2029 is a question the 40.5% remission figure alone cannot answer.
via FDA industry wire (Google News) (Source)
More from Rebecca Stone
Show full bio
Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
10 articles
Linked filings
- K-7275
- K-4971
- V-5532
- V-8592
- C-4460